Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LGI1
REST API REST API
Homo sapiens
LGI1 is differentially expressed in 131 experiments: 168 organism parts: amygdala, lung, ... (166 more);, 110 disease states: normal, lung adenocarcinoma, ... (108 more);, 29 cell types 115 cell lines 15 compound treatments and 58 other conditions.
Synonyms IB1099, ETL1, EPITEMPIN, EPT
Orthologs lgi1a (Danio rerio)   Lgi1 (Mus musculus)   LGI1 (Gallus gallus)   lgi1b (Danio rerio)   Lgi1 (Rattus norvegicus)   lgi1 (Xenopus laevis)   LGI1 (Bos taurus)   LGI1 (Canis familiaris)   (Compare orthologs)
InterPro Term Cys-rich_flank_reg_C, Leu-rich_rpt_typical-subtyp, EAR, Leu-rich_rpt, EPTP
Gene Ontology Term protein binding, cell proliferation, extracellular space, protein homooligomerization, extracellular region, receptor binding, cell junction, axon guidance, neuron projection development, nervous system development, synapse, positive regulation of cell growth, positive regulation of synaptic transmission
UniProt Accession O95970
Gene-Disease Assocation GLIOMA SUSCEPTIBILITY 1; GLM1, EPILEPSY, LATERAL TEMPORAL LOBE, AUTOSOMAL DOMINANT; ADLTE
Search EB-eye ENSG00000108231
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-24147, E-GEOD-2450, E-GEOD-19480, ... (13 experiments)

Factor Value U/D Experiments
NCIH1651
1
E-MTAB-37
HuNS1
1
E-MTAB-37
KHOS240S
1
E-MTAB-37
GM13995
1
E-TABM-321
NB4
1
E-GEOD-12662
SW1463
1
E-MTAB-37
109 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-MEXP-2426, E-GEOD-20033, E-GEOD-3920, ... (20 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-930, E-MEXP-2426
spermatocyte
1
E-TABM-130
B lymphocyte
1
E-GEOD-6691
CD34+ cell
1
E-MEXP-583
native skin
1
E-GEOD-3204
whole blood
1
E-GEOD-3026
23 more value(s).


Disease state

studied in E-GEOD-5390, E-GEOD-3307, E-GEOD-19743, E-GEOD-6872, E-GEOD-15960, ... (23 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-231
normospermic
1
E-GEOD-6872
X-linked dystonia parkinsonism
1
E-GEOD-3064
squamous cell cancer
1
E-MTAB-62
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
1
E-GEOD-3167
osteomyelitis
1
E-MTAB-62
104 more value(s).


Compound treatment

studied in E-GEOD-5418, E-MEXP-1269, E-GEOD-20719, E-GEOD-5258, E-GEOD-3284, ... (12 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-20719, E-GEOD-412, E-GEOD-5418, E-GEOD-2803
glutamine
2
E-MEXP-941, E-MEXP-1335
Cxcl12
1
E-GEOD-7307
4,5-dianilinophthalimide
1
1
E-GEOD-5258
epidermal growth factor
1
E-GEOD-6462
chloroguine
1
E-GEOD-5418
9 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-2666

Disease staging
studied in E-GEOD-19743, E-GEOD-1751

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genotype
studied in E-TABM-321

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446, E-GEOD-9764

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-GEOD-19519, E-GEOD-6919, E-GEOD-16363, E-GEOD-3004, ... (16 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

Performer
studied in E-GEOD-2004

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-1343

Replicate
studied in E-GEOD-10797

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.363 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM